Announced today the start of the latest version of the AliveECG app, with two brand-new FDA-cleared and CE-marked automated detectors that allow individuals and physicians to focus on the ECGs that matter most. The new mobile app immediately detects when an ECG is definitely either Regular or unreadable. THE STANDARD Detector provides added reassurance allowing patients to go about their regular daily activities knowing that no abnormalities were detected within their ECG.Analysis and development expense for the first quarter of 2010 was $33.4 million weighed against $32.3 million for the first quarter of 2009. The boost was due to a milestone payment mainly, additional spending on Phase III clinical trials for pancreatic cancers and melanoma and additional research and development projects, offset by lower spending on our Stage 3 lung cancer clinical trial. Related StoriesSausages With Antioxidants From Berries To Prevent CancerNew findings reveal association between colorectal tumor and melanoma drug treatmentMD Anderson research reveals why chemotherapy drugs not effective for many pancreatic cancers patientsSelling, general and administrative expenses for the first quarter of 2010 increased to $50.4 million compared to $45.1 million for the initial quarter of 2009.